CIRM Funded Clinical Trials

Progenitor Cells Secreting GDNF for the Treatment of ALS

Disease Area:	Amyotrophic Lateral Sclerosis
Investigator:	Clive Svendsen
Institution:	Cedars-Sinai Medical Center
CIRM Grant:	CLIN2-09284 (Closed)
Award Value:	$6,154,067
Trial Sponsor:	Cedars-Sinai Medical Center
Trial Stage:	Phase 1/2
Trial Status:	Completed
Targeted Enrollment:	18
ClinicalTrials.gov ID:	NCT02943850

Clive Svendsen

Details:
ALS is a devastating neurodegenerative disease with no cure that specifically affect a patient's motor neurons in the brain. A team at Cedars-Sinai is transplanting millions of genetically engineered stem cells into patients with ALS. When transplanted into the patient spinal cord, these cells become astrocytes, the support cells that keep nerve cells functioning. Due to the genetic modifications, the cells also deliver high doses of a growth factor which has been shown to protect nerve cells. The goal of this early stage trial is to test the safety of this astrocyte replacement strategy in ALS patients.

Design:
Dose escalation. Open label.

Goal:
Safety. Dosing. Efficacy - Lower limb strength

News about this clinical trial:
CIRM-Funded Clinical Trial for ALS Given Go Ahead to Treat Patients
Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients

Contact Trial Sponsor

Source URL: https://www.cirm.ca.gov/clinical-trial/progenitor-cells-secreting-gdnf-treatment-als